| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278544 | NALPROPION | Compositions for affecting weight loss |
Apr, 2024
(6 months from now) | |
| US8815889 | NALPROPION | Compositions and methods for increasing insulin sensitivity |
Jul, 2024
(9 months from now) | |
| US7462626 | NALPROPION | Compositions for affecting weight loss |
Jul, 2024
(9 months from now) | |
| US7375111 | NALPROPION | Compositions for affecting weight loss |
Mar, 2025
(1 year, 5 months from now) | |
| US9107837 | NALPROPION | Sustained release formulation of naltrexone |
Jun, 2027
(3 years from now) | |
| US8318788 | NALPROPION | Layered pharmaceutical formulations |
Nov, 2027
(4 years from now) | |
| US10307376 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US8722085 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US9125868 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
| US8088786 | NALPROPION | Layered pharmaceutical formulations |
Feb, 2029
(5 years from now) | |
| US11324741 | NALPROPION | Methods for treating visceral fat conditions |
May, 2029
(5 years from now) | |
| US8916195 | NALPROPION | Sustained release formulation of naltrexone |
Feb, 2030
(6 years from now) | |
| US11033543 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2031
(7 years from now) | |
| US9248123 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2032
(8 years from now) | |
| US10403170 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US11139056 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US9633575 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US10835527 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(10 years from now) | |
| US10828294 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(10 years from now) | |
| US10231964 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(10 years from now) | |
Contrave is owned by Nalpropion.
Contrave contains Bupropion Hydrochloride; Naltrexone Hydrochloride.
Contrave has a total of 20 drug patents out of which 0 drug patents have expired.
Contrave was authorised for market use on 10 September, 2014.
Contrave is available in tablet, extended release;oral dosage forms.
Contrave can be used as for effect on blood glucose parameters in patients with insulin resistance, use of naltrexone and bupropion based on an escalating dose schedule, use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder, use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss, use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity, for chronic weight management for treating overweight or obesity.
The generics of Contrave are possible to be released after 02 July, 2034.
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance; Use of naltrexone and bupropion in extended-release form f...
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONTRAVE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic